# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B of A Securities analyst David Li maintains BeiGene (NASDAQ:BGNE) with a Neutral and lowers the price target from $180 to $...
10 worst performing large-cap stocks last week: Walgreens, Floor & Decor, Moderna, Birkenstock, BeiGene, Pool Corp, JD.com,...
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-59...
BeiGene, Ltd. a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® (zanubrutin...
10 worst-performing large-cap stocks last week. National Grid, James Hardie, KE Holdings, JD.Com, XP, Nordson, BeiGene, Lululem...
The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton's tyrosine kinase inh...